comprehensive -WSS

comprehensive

author：knowledge 2025-10-03 01:11:48 - browse：431

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： BD to buy Edwards patient monitoring unit for $4.2 billion

focus

WSS

Midwives could help bridge maternal health disparities in the U.S.

Patients, doctors press FTC to beef up hospital merger scrutiny

Free Covid tests will again be offered to all U.S. households

A new initiative will help leaders fight the next pandemic

PBMs drew scrutiny in House hearing — and so did pharma

FDA panel to weigh safety of artificial wombs for preterm births

entertainment

comprehensive

entertainment

Bright Health sells Medicare Advantage business to Molina

Eli Lilly’s Zepbound improved liver scarring in mid

Anesthesiologist group: stop taking Ozempic before surgery

ASCO Daily Recap: CAR

Guidelines to prevent youth baseball injuries need more muscle

Akili changes sales model for its ADHD video game treatment

Duchenne breakthrough therapy leaves behind pioneering families

Stopping antidepressants leads to symptoms for 1 in 6 patients

In age of alternative facts, a scholarly course on calling out crap

The most pressing bird flu mysteries scientists want answered

focus

Chamber of Commerce, DOJ clash in court over drug prices

An outdated Medicare rule harms dementia patients with anxiety

FDA weighs limits of animal data in assessing artificial wombs

David Liu startup to focus on CRISPR delivery

The most pressing bird flu mysteries scientists want answered

For pregnant people, addiction treatment shouldn't mean a call to child protective services

focus

leisure time

focus

entertainment